Advicenne (Paris: ADVIC) (BSE: ADVIC) (Euronext: ADVIC) today announced the publication of its financial results for the six months ending on June 30, 2020, and provided an update on the company's activities and outlook.

In a statement, Chief Executive Officer Dr. Andre Ulmann reflected on the company's achievements in the difficult context of the COVID-19 health crisis, providing an overview of future developments and thanking the Advicenne team for its dedication: 'During this first half of 2020, Advicenne has continued to prepare the next phase of its development, namely the European launch of its lead drug candidate, ADV7103, in the treatment of a first indication, distal renal tubular acidosis (dRTA), planned for the beginning of 2021. In spite of the challenges brought about by COVID-19, we have also been able to lay the groundwork for our development in the United States, where we have created a subsidiary. Today we are producing the first consolidated accounts in Advicenne's history.

On the basis of my clinical and regulatory experience, I have asked our teams to make good use of the interruption imposed by the health crisis by conducting a thorough review of our American dRTA study protocol, as well as our European cystinuria protocol, with an aim of proposing simplified protocols to the American and European health authorities. These simplifications would allow us to facilitate recruitment and, more generally, an expedited implementation, thus limiting the delay these projects experienced due to the crisis.

We plan to extend the target indication in the United States from dRTA to all genetic forms of RTAs. This will enlarge the population that we target in the US.

Our goal is to obtain marketing authorization for cystinuria in Europe and for RTAs in the United States in H2 2022.

I would like to take this opportunity to express my sincere appreciation to the Advicenne teams in both France and the United States for their exemplary professionalism and engagement.'

2020 Half-Year Highlights

Despite the context of the COVID-19 pandemic, Advicenne's structure was not impacted in the first half of 2020. Already accustomed to telecommuting, the company's teams pursued preparations for the 2021 commercial launch of Advicenne's lead drug candidate, ADV7103, in the treatment of dRTA, in keeping with previously established objectives.

Forward-Looking Statements - Advicenne

This press release contains certain forward-looking statements relating to the business of Advicenne, which shall not be considered per se as historical facts. Such statements include projections and estimates, and the hypotheses on which these are based, as well as observations relating to operations, ongoing projects, objectives, the development of products and their future performance, and expectations regarding financial results.

In some cases, forward-looking statements can be identified by words such as 'could,' 'should,' 'may,' 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates,' 'aims,' 'targets' or similar words. Although the management of Advicenne believes that these forward-looking statements are reasonably made, investors should be aware that they are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. In particular, the expectations of Advicenne could be affected by, among other things, uncertainties involved in the placing on the market and commercialization of Advicenne products or any other risks and uncertainties developed or identified in any public documents filed by Advicenne with the French Financial Markets Authority (Autorite des marches financiers (AMF)), including those listed in chapter 4, 'Risk Factors,' of its reference document, filed with the latter on December 19, 2019, under number D.19-1036. Notwithstanding the compliance with article 223-1 of the General Regulation of the AMF (the information disclosed must be 'accurate, precise and fairly presented'), Advicenne disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Any information relating to the use of drug candidates contained in the present press release is based on the results of ongoing studies at the time of the release's publication. A drug candidate is a product that has not yet received marketing authorization from a health agency.

Contact:

David Solomon

Tel: +33 (0)4 66 05 54 20

Email: investors@advicenne.com

(C) 2020 Electronic News Publishing, source ENP Newswire